156. Rett syndrome Clinical trials / Disease details
Clinical trials : 44 / Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02023424 (ClinicalTrials.gov) | January 2014 | 23/12/2013 | An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome | An Open Label, Exploratory Study to Investigate the Treatment Effect og Glatiramer Acetate (Copaxone ®) on Girls Woth Rett Syndrome | Rett Syndrome | Drug: Glatiramer Acetate (Copaxone®) | Sheba Medical Center | NULL | Recruiting | 6 Years | 15 Years | Female | 10 | Phase 1 | Israel |
| 2 | NCT02153723 (ClinicalTrials.gov) | August 2013 | 26/5/2014 | Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) | Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) | Rett Syndrome | Drug: Glatiramer Acetate | Montefiore Medical Center | Rett Syndrome Research Trust | Completed | 10 Years | N/A | Female | 10 | Phase 2 | United States |